Valneva SE (NASDAQ:VALN) Short Interest Update

Valneva SE (NASDAQ:VALN) was the recipient of a large growth in short interest during the month of March. As of March 15th, there was short interest totalling 16,900 shares, a growth of 191.4% from the February 28th total of 5,800 shares. Based on an average daily volume of 57,400 shares, the short-interest ratio is currently 0.3 days. Approximately 0.0% of the company’s shares are short sold.

Hedge Funds Weigh In On Valneva

A hedge fund recently bought a new stake in Valneva stock. ABC Arbitrage SA acquired a new position in shares of Valneva SE (NASDAQ:VALN) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 19,244 shares of the company’s stock, valued at approximately $84,000. 11.39% of the stock is owned by institutional investors and hedge funds.

Valneva Trading Up 1.3 %

Shares of NASDAQ VALN opened at $7.25 on Friday. Valneva has a fifty-two week low of $3.62 and a fifty-two week high of $9.50. The firm has a market capitalization of $589.14 million, a P/E ratio of -55.77 and a beta of 1.93. The company has a debt-to-equity ratio of 0.70, a current ratio of 2.78 and a quick ratio of 2.25. The company’s 50 day simple moving average is $6.57 and its 200 day simple moving average is $5.61.

Valneva (NASDAQ:VALN) last posted its quarterly earnings results on Thursday, March 20th. The company reported ($0.54) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.32). Valneva had a negative net margin of 4.35% and a negative return on equity of 3.93%. The company had revenue of $56.48 million during the quarter, compared to analyst estimates of $55.64 million. On average, analysts predict that Valneva will post 0.13 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have commented on VALN. HC Wainwright reiterated a “buy” rating and issued a $17.00 price objective on shares of Valneva in a research report on Friday, March 21st. Guggenheim decreased their price target on Valneva from $17.00 to $15.00 and set a “buy” rating on the stock in a report on Monday.

About Valneva

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.